Regen BioPharma Inc (RGBP)
2025-06-30 | 2025-03-31 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenue | 59,065 | 59,065 | 59,065 | |
| Research and development | - | - | 32,500 | |
| Consulting and professional fees | 46,624 | 136,566 | 95,539 | |
| General and administrative | 30,697 | 13,348 | 16,492 | |
| Rent | 22,500 | 22,500 | 22,500 | |
| Total operating expenses | 99,821 | 172,414 | - | |
| Costs and expenses | - | - | 167,031 | |
| Loss from operations | -40,756 | -113,349 | -107,966 | |
| Interest expense attributable to amortization of discount | - | - | -4,339 | |
| Interest expense | 24,638 | 22,329 | 17,554 | |
| Derivative income (expense) | -89,259 | 128,963 | -261 | |
| Interest expense attributable to amortization of discount | 12,639 | 12,639 | - | |
| Total other income (expense), net | -126,536 | 93,995 | -22,154 | |
| Net loss before income taxes | -167,292 | -19,354 | - | |
| Income tax provision | - | - | - | |
| Net loss | -167,292 | -19,354 | -130,120 | |
| Net loss per common share - basic | -0.01 | - | -0.03 | |
| Net loss per common share - diluted | -0.01 | - | -0.03 | |
| Number of weighted average shares - basic | 23,752,506 | 21,554,704 | 4,213,611 | |
| Number of weighted average shares - diluted | 23,752,506 | 21,554,704 | 4,213,611 | |